Previous close | 88.61 |
Open | 88.00 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's range | 86.66 - 88.73 |
52-week range | 60.57 - 96.12 |
Volume | |
Avg. volume | 4,007,522 |
Market cap | 52.976B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 38.27 |
EPS (TTM) | 2.30 |
Earnings date | 24 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 94.52 |
Edwards Lifesciences reports a strong start to 2024 with significant sales increases and raised financial forecasts.
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insights into Edwards Lifesciences' Financial Performance and Strategic Highlights